Chondrosarcoma – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Chondrosarcoma – Pipeline Review, H2 2016’, provides an overview of the Chondrosarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chondrosarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chondrosarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chondrosarcoma

The report reviews pipeline therapeutics for Chondrosarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chondrosarcoma therapeutics and enlists all their major and minor projects

The report assesses Chondrosarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chondrosarcoma

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chondrosarcoma

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chondrosarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Agios Pharmaceuticals, Inc.

Celgene Corporation

CytRx Corporation

EpiZyme, Inc.

Horizon Pharma Plc

Karyopharm Therapeutics, Inc.

Merck & Co., Inc.

Novartis AG

Pfizer Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Chondrosarcoma Overview 7

Therapeutics Development 8

Pipeline Products for Chondrosarcoma - Overview 8

Pipeline Products for Chondrosarcoma - Comparative Analysis 9

Chondrosarcoma - Therapeutics under Development by Companies 10

Chondrosarcoma - Therapeutics under Investigation by Universities/Institutes 11

Chondrosarcoma - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Chondrosarcoma - Products under Development by Companies 14

Chondrosarcoma - Products under Investigation by Universities/Institutes 15

Chondrosarcoma - Companies Involved in Therapeutics Development 16

Agios Pharmaceuticals, Inc. 16

Celgene Corporation 17

CytRx Corporation 18

EpiZyme, Inc. 19

Horizon Pharma Plc 20

Karyopharm Therapeutics, Inc. 21

Merck & Co., Inc. 22

Novartis AG 23

Pfizer Inc. 24

Chondrosarcoma - Therapeutics Assessment 25

Assessment by Monotherapy Products 25

Assessment by Target 26

Assessment by Mechanism of Action 28

Assessment by Route of Administration 30

Assessment by Molecule Type 32

Drug Profiles 34

AG-120 - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

aldoxorubicin hydrochloride - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

axitinib - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

enasidenib mesylate - Drug Profile 60

Product Description 60

Mechanism Of Action 60

R&D Progress 60

interferon gamma-1b - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

pazopanib hydrochloride - Drug Profile 70

Product Description 70

Mechanism Of Action 70

R&D Progress 70

pembrolizumab - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

Peptide to Inhibit c-Myc and mTOR for Chondrosarcoma and Oncology - Drug Profile 114

Product Description 114

Mechanism Of Action 114

R&D Progress 114

Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile 115

Product Description 115

Mechanism Of Action 115

R&D Progress 115

selinexor - Drug Profile 117

Product Description 117

Mechanism Of Action 117

R&D Progress 117

sirolimus - Drug Profile 136

Product Description 136

Mechanism Of Action 136

R&D Progress 136

tazemetostat - Drug Profile 137

Product Description 137

Mechanism Of Action 137

R&D Progress 137

Chondrosarcoma - Dormant Projects 145

Chondrosarcoma - Discontinued Products 146

Appendix 147

Methodology 147

Coverage 147

Secondary Research 147

Primary Research 147

Expert Panel Validation 147

Contact Us 147

Disclaimer 148

List of Tables

List of Tables

Number of Products under Development for Chondrosarcoma, H2 2016 8

Number of Products under Development for Chondrosarcoma – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Chondrosarcoma – Pipeline by Agios Pharmaceuticals, Inc., H2 2016 16

Chondrosarcoma – Pipeline by Celgene Corporation, H2 2016 17

Chondrosarcoma – Pipeline by CytRx Corporation, H2 2016 18

Chondrosarcoma – Pipeline by EpiZyme, Inc., H2 2016 19

Chondrosarcoma – Pipeline by Horizon Pharma Plc, H2 2016 20

Chondrosarcoma – Pipeline by Karyopharm Therapeutics, Inc., H2 2016 21

Chondrosarcoma – Pipeline by Merck & Co., Inc., H2 2016 22

Chondrosarcoma – Pipeline by Novartis AG, H2 2016 23

Chondrosarcoma – Pipeline by Pfizer Inc., H2 2016 24

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Stage and Target, H2 2016 27

Number of Products by Stage and Mechanism of Action, H2 2016 29

Number of Products by Stage and Route of Administration, H2 2016 31

Number of Products by Stage and Molecule Type, H2 2016 33

Chondrosarcoma – Dormant Projects, H2 2016 145

Chondrosarcoma – Discontinued Products, H2 2016 146

List of Figures

List of Figures

Number of Products under Development for Chondrosarcoma, H2 2016 8

Number of Products under Development for Chondrosarcoma – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Assessment by Monotherapy Products, H2 2016 25

Number of Products by Top 10 Targets, H2 2016 26

Number of Products by Stage and Top 10 Targets, H2 2016 26

Number of Products by Top 10 Mechanism of Actions, H2 2016 28

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 28

Number of Products by Routes of Administration, H2 2016 30

Number of Products by Stage and Routes of Administration, H2 2016 30

Number of Products by Molecule Types, H2 2016 32

Number of Products by Stage and Molecule Types, H2 2016 32

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports